Categories for COVID-19/Coronavirus
Capricor Therapeutics, a clinical-stage biotechnology company focused on the development of the first-in-class cell and exosome-based therapeutics for the treatment and prevention of serious diseases, and Lonza today announced that the companies have entered into an agreement for the development of CAP-1002, Capricor's leading clinical asset using allogeneic cardiosphere-derived cells (CDC) technology for the treatment of Duchenne Muscular Dystrophy (DMD) and complications arising from COVID-19.
2020 saw SOCMA’s Government Relations team continuing its efforts in support of the Specialty & Fine Chemical industry. With the... View Article
SOCMA member Lonza congratulates Moderna on interim Phase 3 clinical trial data.
Lonza announced today that the company has signed
an agreement with AstraZeneca to manufacture AZD7442, a combination of two long-acting antibodies (LAABs) for the potential prevention and treatment of COVID-19.
Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper response called ‘cytokine storm,’ and Lonza today announced a strategic collaboration to expand the manufacturing capacity for lenzilumab, currently in Phase 3 clinical trials for COVID-19, in advance of potential Emergency Use Authorization in 2020 and subsequent commercialization.
COVID-19 Resources for the Specialty Chemical Industry SOCMA continues to monitor the impacts of COVID-19 on business continuity related to... View Article
OSHA has issued two revised guidance memos on recordkeeping and enforcement in response to the COVID-19 pandemic. On May 26, 2020, the previous memos from April on these topics will be rescinded, and the new memos will go into and remain in effect until further notice.
Internationally respected demographer, Ken Gronbach, stated the U.S. economy would not suffer as a result of COVID-19 because of it's position in the global landscape.
In this post, SOCMA shares the following core considerations for developing return to work plans. The following information was compiled based on information shared during a SOCMA roundtable with DanChem, Strem Chemicals, Inc and Sun Chemical Corporation. A template return to work plan is in development and will be available in the coming week.
Moderna, Inc. and Lonza Ltd. today announced a 10-year strategic collaboration agreement to enable larger scale manufacture of Moderna's mRNA vaccine (mRNA-1273) against the novel coronavirus (SARS-CoV-2) and additional Moderna products in the future.